1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
180 Life Sciences Corporation was founded in 2007 with the goal of revolutionizing the healthcare industry. The company quickly grew to become one of the leading biotechnology companies in the world, driven by its focus on innovation and customer service. 180 Life Sciences Corporation is dedicated to providing innovative solutions for the healthcare industry, and has developed products and technologies to expedite drug discovery and better diagnose diseases.
180 Life Sciences Corporation's mission is to use innovative technologies to create better treatments and diagnoses for medical conditions and diseases.
At 180 Life Sciences Corporation, our vision is to continue to challenge the healthcare industry and provide innovative solutions to improve patient care.
